Publications by authors named "Michael Ojelabi"
Article Synopsis
- The study examines outcomes of older patients (60+) with Acute Myeloid Leukemia (AML) based on whether they received treatment at community or academic cancer centers during clinical trials.
- Results indicate that there were similar levels of adverse events, 1-month mortality rates, and overall survival between the two types of centers, with 17% of participants enrolled in community centers.
- The findings suggest that intensive chemotherapy trials can be effectively conducted in select community cancer centers, offering comparable treatment outcomes to those at academic institutions for older patients with complex health needs.
Purpose: This study determined whether an electronic version of the geriatric assessment is feasible in a multi-institutional, diverse setting.
Methods: Ten sites within the Alliance for Clinical Trials in Oncology participated. Patients who had active cancer or a history of cancer and were 65 years of age or older were eligible.